# US 2008/0188524 A1 · Methods of treating pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188524 A1
- Document ID: US20080188524A1
- Status: Published application
- Kind: A1
- Application number: 11/977,275
- Filed: 2007-10-24
- Published: 2008-08-07
- Earliest claimed: 2006-10-25
- Inventors: Martin Augustin; Lutz Zeitlmann; Gabriele Stumm; Michael A. Pleiss; Philipp Wabnitz; Hans Allgeier
- Web page: https://patentgrep.com/patent/US20080188524A1

## CPC

- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for the treatment of pain comprises administering a to a subject in need thereof an amount of at least one inhibitor of a cyclin-dependent kinase (CDK). Preferably, the inhibitor of a cyclin-dependent kinase comprises a thiazole of general Formula I, II or III as desribed herein.

## Claims

### Claim 1

A method for the treatment of pain comprising administering to a subject in need thereof an amount of at least one inhibitor of a cyclin-dependent kinase (CDK) sufficient to elicit a hypoalgesic effect.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said at least one inhibitor of a cyclin-dependent kinase comprises a thiazole of general Formula I, II or III:
wherein
R1 and R2 are independently hydrogen, fluorine or alkyl;
R3 is aryl or heteroaryl;
R4 is hydrogen, alkyl, cycloalkyl, aryl, cycloalkylalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl; or CO-alkyl, CO-cycloalkyl, CO-aryl, CO-alkyl-cycloalkyl, CO-alkyl-aryl, CO-heteroaryl, CO-alkyl-heteroaryl, CO-heterocycloalkyl, CO-alkyl-heterocycloalkyl; or CONH-alkyl, CONH-cycloalkyl, CONH-aryl, CONH-alkyl-cycloalkyl, CONH-alkyl-aryl, CONH-heteroaryl, CONH-alkyl-heteroaryl, CONH-heterocycloalkyl, CONH-alkyl-heterocycloalkyl; or COO-alkyl, COO-cycloalkyl, COO-aryl, COO-alkyl-cycloalkyl, COO-alkyl-aryl, COO-heteroaryl, COO-alkyl-heteroaryl, COO-heterocycloalkyl, COO-alkyl-heterocycloalkyl; or SO2-alkyl, SO2-cycloalkyl, SO2-aryl, SO2-alkyl-cycloalkyl, SO2-alkyl-aryl, SO2-heteroaryl, SO2-alkyl-heteroaryl, SO2-heterocycloalkyl, SO2-alkyl-heterocycloalkyl; or C(NCN)NH-alkyl, C(NCN)NH-cycloalkyl, C(NCN)NH-aryl, C(NCNNH)-alkyl-cycloalkyl, C(NCN)NH-alkyl-aryl, C(NCN)NH-heteroaryl, C(NCN)NH-alkyl-heteroaryl, C(NCN)NH-heterocycloalkyl, C(NCN)NH-alkyl-heterocylcoalkyl; or C(NNO2)NH-alkyl, C(NNO2)NH-cycloalkyl, C(NNO2)NH-aryl, C(NNO2)NH-alkyl-cycloalkyl, C(NNO2)NH-alkyl-aryl, C(NNO2)NH-heteroaryl, C(NNO2)NH-alkyl-heteroaryl, C(NNO2)NH-heterocyloalkyl, C(NNO2)NH-alkyl-heterocycloalkyl; or C(NH)NH-alkyl, C(NH)NH-cycloalkyl, C(NH)NH-aryl, C(NH)NH-alkyl-cycloalkyl, C(NH)NH-alkyl-aryl, C(NH)NH-heteroaryl, C(NH)NH-alkyl-heteroaryl, C(NH)NH-heterocycloalkyl, C(NH)NH-alkyl-heterocycloalkyl; or C(NH)NHCO-alkyl, C(NH)NHCO-cycloalkyl, C(NH)NHCO-aryl, C(NH)NHCO-alkyl-cycloalkyl, C(NH)NHCO-alkyl-aryl, C(NH)NHCO-heteroaryl, C(NH)NHCO-alkyl-heteroaryl, C(NH)NHCO-heterocylcloalkyl, C(NH)NHCO-alkyl-heterocycloalkyl; or C(NOR6)NH-alkyl, C(NOR6)NH-cycloalkyl, C(NOR6)NH-aryl, C(NOR6)NH-alkyl-cycloalkyl, C(NOR6)NH-alkyl-aryl, C(NOR6)NH-heteroaryl, C(NOR6)NH-alkyl-heteroaryl, C(NOR6)NH-heterocylcoalkyl, or C(NOR6)NH-alkyl-heterocycloalkyl;
R5 is hydrogen or alkyl;
R6 is hydrogen, alkyl, cycloalkyl, aryl, cycloalkylalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;
R7 is alkyl;
R8 is hydrogen or alkyl;
R9 and R10 are each independently hydrogen, alkyl, substituted alkyl, cycloalkyl or substituted cycloalkyl;
R11 is hydrogen or alkyl substituted with one or two hydroxyl groups or with an amino group; R15 is hydrogen or alkyl; or R15 and R11 taken together are —(CH2)q— where q is 3, 4, 5 or 6;
R14 is hydrogen or alkyl;
X is CH or N;
Z is NR9 or CHNR9R10;
m is 0, 1, or 2;
n is 1, 2, or 3;
E is a covalent bond or (CH2)p; and
p is 1, 2 or 3;
and enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the thiazole is characterized by general Formula I, wherein
R1 and R2 are independently hydrogen, fluorine or alkyl;
wherein Y is oxygen, sulfur or NR9;
R4 is alkyl, cycloalkyl, aryl, cyoloalkylalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, or CO-alkyl, CO-cycloalkyl, CO-aryl, CO-alkyl-cycloalkyl, CO-alkyl-aryl, CO-heteroaryl, CO-alkyl-heteroaryl, CO-heterocycloalkyl, CO-alkyl-heterocycloalkyl; or CONH-alkyl, CONH-cycloalkyl, CONH-aryl, CONH-alkyl-cycloalkyl, CONH-alkyl-aryl, CONH-heteroaryl, CONH-alkyl-heteroaryl, CONH-heterocycloalkyl, CONH-alkyl-heterocycloalkyl; or COO-alkyl, COO-cycloalkyl, COO-aryl, COO-alkyl-cycloalkyl, COO-alkyl-aryl, COO-heteroaryl, COO-alkyl-heteroaryl, COO-heterocycloalkyl, COO-alkyl-heterocycloalkyl; or SO2-cycloalkyl, SO2-aryl, SO2-alkyl-cycloalkyl, SO2-alkyl-aryl, SO2-heteroaryl, SO2-alkyl-heteroaryl, SO2-heterocycloalkyl, SO2-alkyl-heterocycloalkyl; or C(NCN)NH-alkyl, C(NCN)NH-cycloalkyl, C(NCN)NH-aryl, C(NCNNH)-alkyl-cycloalkyl, C(NCN)NH-alkyl-aryl, C(NCN)NH-heteroaryl, C(NCN)NH-alkyl-heteroaryl, C(NCN)NH-heterocycloalkyl, C(NCN)NH-alkyl-heterocylcoalkyl; or C(NNO2)NH-alkyl, C(NNO2)NH-cycloalkyl, C(NNO2)NH-aryl, C(NNO2)NH-alkyl-cycloalkyl, C(NNO2)NH-alkyl-aryl, C(NNO2)NH-heteroaryl, C(NNO2)NH-alkyl-heteroaryl, C(NNO2)NH-heterocyloalkyl, C(NNO2)NH-alkyl-heterocycloalkyl; or C(NH)NH-alkyl, C(NH)NH-cycloalkyl, C(NH)NH-aryl, C(NH)NH-alkyl-cycloalkyl, C(NH)NH-alkyl-aryl, C(NH)NH-heteroaryl, C(NH)NH-alkyl-heteroaryl, C(NH)NH-heterocycloalkyl, C(NH)NH-alkyl-heterocycloalkyl; or C(NH)NHCO-alkyl, C(NH)NHCO-cycloalkyl, C(NH)NHCO-aryl, C(NH)NHCO-alkyl-cycloalkyl, C(NH)NHC alkyl-aryl, C(NH)NHCO-heteroaryl, C(NH)NHCO-alkyl-heteroaryl, C(NH)NHCO-heterocylcloalkyl, C(NH)NHCO-alkyl-heterocycloalkyl; or C(NOR6)NH-alkyl, C(NOR6)NH-cycloalkyl, C(NOR6)NH-aryl, C(NOR6)NH-alkyl-cycloalkyl, C(NOR6)NH-alkyl-aryl, C(NOR6)NH-heteroaryl, C(NOR6)NH-alkyl-heteroaryl, C(NOR6)NH-heterocylcoalkyl, C(NOR6)NH-alkyl-heterocycloalkyl;
R5 is hydrogen or alkyl;
R6 is hydrogen, alkyl, cycloalkyl, aryl, cycloalkylalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;
R7 and R8 are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, cycloalkylalkyl, arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkyalkyl; and
R9 is hydrogen, alkyl, cycloalkyl, aryl, alkylcycloalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the thiazole characterized by general Formula I, wherein
R1 and R2 are independently hydrogen, fluorine or alkyl;
wherein Y is oxygen;
R4 is CO-alkyl, CO-alkyl-aryl, CO-cycloalkyl, CO-alkyl-heteroaryl, CO-alkyl-heteroalkyl, CO-alkyl-heterocycloalkyl, CONH-alkyl, CONH-alkyl-aryl, CONH-cycloalkyl, or CONH-alkyl-heterocycloalkyl;
R5 is hydrogen; and
R7 and R8 are hydrogen;
m is 0; and
n is 1.

### Claim 5 (depends on 2)

The method according to claim 2, wherein the thiazole is characterized by general Formula I, wherein
R1 and R2 are independently hydrogen, fluorine or alkyl;
wherein Y is oxygen;
R4 is CO-alkyl, CO-alkyl-aryl, CO-alkyl-heteroalkyl, CO-cycloalkyl, CO-alkyl-heterocycloalkyl, CO-alkyl-heteroaryl, CONH-alkyl, CONH-alkyl-aryl, CONH-cycloalkyl, or CONH-alkyl-heterocycloalkyl;
R5 is hydrogen;
R7 and R8 are alkyl;
m is 0; and
n is 1.

### Claim 6 (depends on 2)

The method according to claim 2, wherein the thiazole is characterized by general Formula I, wherein
R1 and R2 are independently hydrogen, fluorine or alkyl;
wherein Y is oxygen;
R4 is CO-alkyl, CO-alkyl-aryl, CO-alkyl-heteroalkyl, CO-cycloalkyl, CO-alkyl-heterocycloalkyl, CO-alkyl-heteroaryl, CONH-alkyl, CONH-alkyl-aryl, CONH-cycloalkyl, or CONH-alkyl-heterocycloalkyl;
R5 is hydrogen;
R7 is hydrogen;
R8 is alkyl;
m is 0; and
n is 1.

### Claim 7 (depends on 2)

The method according to claim 2, wherein said the thiazole is characterized by general Formula I, wherein
R1 and R2 are independently hydrogen, fluorine or alkyl;
wherein Y is oxygen;
R4 is CO-alkyl, CO-alkyl-aryl, CO-alkyl-heteroalkyl, CO-cycloalkyl, CO-alkyl-heterocycloalkyl, CO-alkyl-heteroaryl, CONH-alkyl, CONH-alkyl-aryl, CONH-cycloalkyl, or CONH-alkyl-heterocycloalkyl;
R5 is hydrogen;
R7 is alkyl;
R8 is hydrogen;
m is 0; and
n is 1.

### Claim 8 (depends on 2)

The method according to claim 2, wherein the thiazole is characterized by general Formula I, wherein
R1 and R2 are independently hydrogen, fluorine or alkyl;
wherein Y is sulfur;
R4 is CO-alkyl, CO-alkyl-aryl, CO-alkyl-heteroalkyl, CO-cycloalkyl, CO-alkyl-heterocycloalkyl, CO-alkyl-heteroaryl, CONH-alkyl, CONH-alkyl-aryl, CONH-cycloalkyl, or CONH-alkyl-heterocycloalkyl;
R5 is hydrogen;
R7 is hydrogen;
R8 is alkyl;
m is 0; and
n is 1.

### Claim 9 (depends on 2)

The method according to claim 2, wherein the thiazole is characterized by general Formula I, wherein
R1 and R2 are independently hydrogen, fluorine or alkyl;
wherein Y is sulfur;
R4 is CO-alkyl, CO-alkyl-aryl, CO-alkyl-heteroalkyl, CO-cycloalkyl, CO-alkyl-heterocycloalkyl, CO-alkyl-heteroaryl, CONH-alkyl, CONH-alkyl-aryl, CONH-cycloalkyl, or CONH-alkyl-heterocycloalkyl;
R5 is hydrogen;
R7 is alkyl;
R8 is hydrogen;
m is 0; and
n is 1.

### Claim 10 (depends on 2)

The method according to claim 2, wherein the thiazole is characterized by general Formula I, wherein
R1 and R2 are independently hydrogen, fluorine or alkyl;
wherein Y is NR9;
R4 is CO-alkyl, CO-alkyl-aryl, CO-alkyl-heteroalkyl, CO-cycloalkyl, CO-alkyl-heterocycloalkyl, CO-alkyl-heteroaryl, CONH-alkyl, CONH-alkyl-aryl, CONH-cycloalkyl, or CONH-alkyl-heterocycloalkyl;
R5 is hydrogen;
R7 is hydrogen;
R8 is alkyl;
R9 is hydrogen, alkyl, cycloalkyl, aryl, alkyl-cycloalkyl, alkyl-aryl, heteroaryl, alkyl-heteroaryl, heterocycloalkyl, or alkyl-heterocycloalkyl;
m is 0; and
n is 1.

### Claim 11 (depends on 2)

The method according to claim 2, wherein the thiazole is characterized by general Formula I, wherein
R1 and R2 are independently hydrogen, fluorine or alkyl;
wherein Y is NR9;
R4 is CO-alkyl, CO-alkyl-aryl, CO-alkyl-heteroalkyl, CO-cycloalkyl, CO-alkyl-heterocycloalkyl, CO-alkyl-heteroaryl, CONH-alkyl, CONH-alkyl-aryl, CONH-cycloalkyl, or CONH-alkyl-heterocycloalkyl;
R5 is hydrogen;
R7 is alkyl;
R8 is hydrogen;
R9 is alkyl;
m is 0; and
n is 1.

### Claim 12 (depends on 2)

The method according to claim 2, wherein the thiazole is characterized by general Formula I, wherein
R1 and R2 are independently hydrogen, fluorine or alkyl;
wherein Y is NR9;
R4 is CO-alkyl, CO-alkyl-aryl, CO-cycloalkyl, CO-alkyj-heteroaryl, CO-alkyl-heteroalkyl, CO-alkyl-heterocycloalkyl, CONH-alkyl, CONH-alkyl-aryl, CONH-cycloalkyl, or CONH-alkyl-heterocycloalkyl;
R5 is hydrogen;
R7 is alkyl;
R8 is hydrogen;
R9 is hydrogen;
m is 0; and
n is 1.

### Claim 13 (depends on 2)

The method according to claim 2, wherein the thiazole is characterized by general Formula I, and is selected from the group consisting of:
N-[5-[[5-Ethyl-2-oxazolyl)methyl]thio]-2-thiazoly]acetamide;
N-[5-[[5-Ethyl-2-oxazolyl)methyl]thio]-2-thiazolyl]benzamide;
N-[5-[[5-Ethyl-2-oxazolyl)methyl]thio]-2-thiazolyl]benzenesulfonamide;
N-[5-[[(4,5-Dimethyl-2-oxazolyl)methyl]thio]-2-thiazolyl]acetamide;
N-[5-[[(5-t-Butyl-2-oxazolyl)methyl]thio]-2-thiazolyl]acetamide;
N-[5-[[5-t-Butyl-2-oxazolyl)methyl]thio]-2-thiazolyl]trimethylacetamide;
N-[5-[[(4-Ethyl-2-oxazolyl)methyl]thio]-2-thiazolyl]acetamide;
N-[5-[[(5-t-Butyl-2-oxazolyl)methyl]thio]-2-thiazolyl]-N′-cyano-N″-(2,6-difluorophenyl)guanidine;
N-[5-[[(5-Isopropyl-2-oxazolyl)fluoromethyl]thio]-2-thiazolyl]acetamide;
N-[5-[[(5-t-Butyl-2-oxazolyl)methyl]thio]-2-thiazolyl]aminophenyl-4-(2-hydroxyethyl)sulfonamide;
N-[5-[[(5-t-Butyl-2-oxazolyl)methyl]thio]-2-thiazolyl]aminophenyl-4-sulfonamide;
N-[5-[[(5-t-Butyl-2-oxazolyl)methyl]thio]-2-thiazolyl]-4-aminopyrimidine;
N-[5-[[(5-t-Butyl-2-oxazolyl)methyl]thio]-2-thiazolyl]-3-(hydroxymethyl)aniline;
N-[5-[[(5-t-Butyl-2-oxazolyl)methyl]thio]-2-thiazolyl]-2-aminopyridine;
N-[5-[[(5-t-Butyl-2-oxazolyl)methyl]thio]-2-thiazolyl]-2-[5-[(((3-hydroxy-2,2-dimethyl)propyl)amino)methyl]]aminopyridine;
N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]-methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide; and
a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 2)

The method according to claim 2, wherein the thiazole is characterized by general Formula II:
wherein R7 is alkyl; R8 is hydrogen or alkyl; Z is NR9 or CHNR9R10; and R9 and R10 are each independently hydrogen, alkyl, substituted alkyl, cycloalkyl or substituted cycloalkyl.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the thiazole is characterized by general Formula IIa:
wherein R9 is hydrogen, alkyl, substituted alkyl or cycloalkyl.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the thiazole is characterized by general Formula IIb:
wherein R9 is alkyl, substituted alkyl or cycloalkyl.

### Claim 17 (depends on 14)

The method according to claim 14, wherein the thiazole is characterized by general Formula IIc:
wherein R9 and R10 are each independently hydrogen, alkyl, substituted alkyl or cycloalkyl with the proviso that both R9 and R10 are not hydrogen.

### Claim 18 (depends on 14)

The method according to claim 14, wherein the thiazole is selected from the group consisting of:
(±)-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-3-piperidinecarboxamide;
(±)-1-(2,3-dihydroxypropyl)-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide;
N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-1-(1-methylethyl)-4-piperidinecarboxamide;
1-cyclopropyl-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide;
N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-1-(2-hydroxyethyl)-4-piperidinecarboxamide;
(R)-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-3-piperidinecarboxamide;
(S)-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-3-piperidinecarboxamide;
cis-4-amino-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]cyclohexylcarboxamide; and
trans-4-amino-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]cyclohexylcarboxamide; and
a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 2)

The method according to claim 2, wherein the thiazole is characterized by general Formula III:
wherein
R7 is alkyl;
R8 and R14 are each independently hydrogen or alkyl; and X is CH or N.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the thiazole is characterized by general Formula IIIa:
wherein
R8 and R14 are each independently hydrogen or methyl; and
R15 is hydrogen, and R11 is hydrogen, —CH2C(CH3)2CH2OH, —CH2CH2OH, —C(CH3)2CH2OH, —CH(CH2OH)2, —CH2CH(OH)CH2OH, —CH(CH3)CH2OH or
or
R15 and R11 taken together are —(CH2)4—.

### Claim 21 (depends on 19)

The method according to claim 19, wherein the thiazole is characterized by general Formula IIIb:
wherein
R8 and R14 are each independently hydrogen or methyl; and
R15 is hydrogen, and R11 is hydrogen, —CH2C(CH3)2CH2OH, —CH2CH2OH, —C(CH3)2CH2OH, —CH(CH2OH)2, —CH2CH(OH)CH2OH, —CH(CH3)CH2OH or
or R15 and R11 taken together are —(CH2)4—.

### Claim 22 (depends on 19)

The method according to claim 19, wherein the thiazole is characterized by general Formula IIIc:
wherein
R8 and R14 are each independently hydrogen or methyl; and
R15 is hydrogen, and R11 is hydrogen, —CH2C(CH3)2CH2OH, —CH2CH2OH, —C(CH3)2CH2OH, —CH(CH2OH)2, —CH2CH(OH)CH2OH, —CH(CH3)CH2OH or
or R15 and R11 taken together are —(CH2)4—.

### Claim 23 (depends on 19)

The method according to claim 19, wherein the thiazole is selected from the group consisting of:
N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-[[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]methyl]benzeneacetamide;
4-[[(2,3-dihydroxypropyl)amino]methyl]-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]benzeneacetamide;
(R)-4-[[(2,3-dihydroxypropyl)amino]methyl]-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]benzeneacetamide;
(S)-4-[[(2,3-dihydroxypropyl)amino]methyl]-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]benzeneacetamide;
4-(aminomethyl)-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]benzeneacetamide;
N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-[[(3-hydroxy-2,2-dimethylpropyl)amino]methyl]benzeneacetamide;
N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-(1-pyrrolidinylmethyl)benzeneacetamide;
N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-[[(2-hydroxyethyl)amino]methyl]benzeneacetamide;
N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazoly]-4-[[[2-(1pyrrolidinyl)ethyl]amino]methyl]benzeneacetamide;
N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-[[(2-hydroxy-1,1-dimethylethyl)amino]methyl]benzeneacetamide;
N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-3-[[(2-hydroxyethyl)amino]methyl]benzeneacetamide;
N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-3-[[(3-hydroxy-2,2-dimethylpropyl)amino]methyl]benzeneacetamide;
3-(aminomethyl)-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]benzeneacetamide;
N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-[[(2-hydroxy-1-methylethyl)amino]methyl]benzeneacetamide;
N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-[1-[(2-hydroxyethyl)amino]ethyl]benzeneacetamide;
N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-[1-[(2-hydroxy-1-methylethyl)amino]ethyl]benzeneacetamide;
(α)-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-[[(2-hydroxyethyl)amino]methyl]-.alpha.-methylbenzeneacetamide;
N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-6-[[(2-hydroxyethyl)amino]methyl]-3-pyridineacetamide; and
N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-[[(2-hydroxyethyl)amino]methyl]-α-methylbenzeneacetamide; and
a pharmaceutically acceptable salt thereof.

### Claim 24

A thiazole selected from the group consisting of:
(±)-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-3-piperidinecarboxamide;
(R)—N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazoly]-3-piperidinecarboxamide;
(S)—N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazoly]-3-piperidinecarboxamide;
cis-4-amino-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]cyclohexylcarboxamide;
trans-4-amino-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]cyclohexylcarboxamide;
N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-[[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]methyl]benzeneacetamide;
N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl-4-[[(2-hydroxy-1,1-dimethylethyl)amino]methyl]benzeneacetamide;
4-[[(2,3-Dihydroxypropyl)amino]methyl]-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]benzeneacetamide;
(R)-4-[[(2,3-Dihydroxypropyl)amino]methyl]-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]benzeneacetamide;
(S)-4-[[(2,3-Dihydroxypropyl)amino]methyl]-N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]benzeneacetamide; and
a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 1)

The method according to claim 1, wherein said pain is selected from the group comprising chronic pain, inflammatory pain, and neuropathic pain.

### Claim 26

A pharmaceutical composition comprising at least one inhibitor of a cyclin-dependent kinase, wherein said at least one inhibitor is a thiazole characterized by any one of general Formula I, II or III:
wherein
R1 and R2 are independently hydrogen, fluorine or alkyl;
R3 is aryl or heteroaryl;
R4 is hydrogen, alkyl, cycloalkyl, aryl, cycloalkylalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl; or CO-alkyl, CO-cycloalkyl, CO-aryl, CO-alkyl-cycloalkyl, CO-alkyl-aryl, CO-heteroaryl, CO-alkyl-heteroaryl, CO-heterocycloalkyl, CO-alkyl-heterocycloalkyl; or CONH-alkyl, CONH-cycloalkyl, CONH-aryl, CONH-alkyl-cycloalkyl, CONH-alkyl-aryl, CONH-heteroaryl, CONH-alkyl-heteroaryl, CONH-heterocycloalkyl, CONH-alkyl-heterocycloalkyl; or COO-alkyl, COO-cycloalkyl, COO-aryl, COO-alkyl-cycloalkyl, COO-alkyl-aryl, COO-heteroaryl, COO-alkyl-heteroaryl, COO-heterocycloalkyl, COO-alkyl-heterocycloalkyl; or SO2-alkyl, SO2-cycloalkyl, SO2-aryl, SO2-alkyl-cycloalkyl, SO2-alkyl-aryl, SO2-heteroaryl, SO2-alkyl-heteroaryl, SO2-heterocycloalkyl, SO2-alkyl-heterocycloalkyl; or C(NCN)NH-alkyl, C(NCN)NH-cycloalkyl, C(NCN)NH-aryl, C(NCNNH)-alkyl-cycloalkyl, C(NCN)NH-alkyl-aryl, C(NCN)NH-heteroaryl, C(NCN)NH-alkyl-heteroaryl, C(NCN)NH-heterocycloalkyl, C(NCN)NH-alkyl-heterocylcoalkyl; or C(NNO2)NH-alkyl, C(NNO2)NH-cycloalkyl, C(NNO2)NH-aryl, C(NNO2)NH-alkyl-cycloalkyl, C(NNO2)NH-alkyl-aryl, C(NNO2)NH-heteroaryl, C(NNO2)NH-alkyl-heteroaryl, C(NNO2)NH-heterocyloalkyl, C(NNO2)NH-alkyl-heterocycloalkyl; or C(NH)NH-alkyl, C(NH)NH-cycloalkyl, C(NH)NH-aryl, C(NH)NH-alkyl-cycloalkyl, C(NH)NH-alkyl-aryI, C(NH)NH-heteroaryl, C(NH)NH-alkyl-heteroaryl, C(NH)NH-heterocycloalkyl, C(NH)NH-alkyl-heterocycloalkyl; or C(NH)NHCO-alkyl, C(NH)NHCO-cycloalkyl, C(NH)NHCO-aryl, C(NH)NHCO-alkyl-cycloalkyl, C(NH)NHCO-alkyl-aryl, C(NH)NHCO-heteroaryl, C(NH)NHCO-alkyl-heteroaryl, C(NH)NHCO-heterocylcloalkyl, C(NH)NHCO-alkyl-heterocycloalkyl; or C(NOR6)NH-alkyl, C(NOR6)NH-cycloalkyl, C(NOR6)NH-aryl, C(NOR6)NH-alkyl-cycloalkyl, C(NOR6)NH-alkyl-aryl, C(NOR6)NH-heteroaryl, C(NOR6)NH-alkyl-heteroaryl, C(NOR6)NH-heterocylcoalkyl, or C(NOR6)NH-alkyl-heterocycloalkyl;
R5 is hydrogen or alkyl;
R6 is hydrogen, alkyl, cycloalkyl, aryl, cycloalkylalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;
R7 is alkyl;
R8 is hydrogen or alkyl;
R9 and R10 are each independently hydrogen, alkyl, substituted alkyl, cycloalkyl or substituted cycloalkyl;
R11 is hydrogen or alkyl substituted with one or two hydroxyl groups or with an amino group; R15 is hydrogen or alkyl; or R15 and R11 taken together are —(CH2)q— where q is 3, 4, 5 or 6;
R14 is hydrogen or alkyl;
X is CH or N;
Z is NR9 or CHNR9R10;
m is 0, 1, or 2;
n is 1, 2, or 3;
E is a covalent bond or (CH2)p; and
p is 1, 2 or 3;
and enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

### Claim 27 (depends on 26)

The pharmaceutical composition according to claim 26, wherein said at least one inhibitor of a cyclin-dependent kinase is N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl)methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers, mixtures of isomers, enantiomers, diastereomers, and the pharmaceutically acceptable salts and solvates thereof.
